Astonea Labs Approves Audited Consolidated Financial Results for FY26

Astonea Labs Limited announced that its Board of Directors, in a meeting held on July 24, 2026, approved the Audited Consolidated Financial Results for the half-year and financial year ended March 31, 2026. The approval was delayed due to the pending audit report of its associate company, Damaira Pharmaceuticals Private Limited. The company also took on record the Statutory Auditors' Report, which contained an unmodified opinion. The Board further approved the Board's Report and the Annual Report for the financial year 2025-26. The trading window for securities will reopen 48 hours after the declaration of these results.